

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

**FURTHER DELAY IN DISPATCH OF CIRCULAR
IN RELATION TO MAJOR TRANSACTION CONCERNING
SECOND AMENDMENTS TO THE TERMS AND CONDITIONS OF
THE CONVERTIBLE BONDS**

Reference is made to the announcement of the Company dated 12 May 2021 in relation to, among other things, the Second Amendments and the entering into the Second Amendment Deed which constitutes a major transaction under Chapter 14 of the Listing Rules (the “**Announcement**”), and the announcement of the Company dated 30 June 2021 regarding the delay in dispatch of the Circular (the “**Delay Announcement**”). Capitalized terms used herein shall have the same meanings as those defined in the Announcement and the Delay Announcement unless the context requires otherwise.

As disclosed in the Delay Announcement, the Circular will be dispatched to the Shareholders on or before 12 July 2021.

As additional time is required for bulk printing of the Circular, it is expected that the Circular will be dispatched to the Shareholders on 14 July 2021.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 12 July 2021

As at the date of this announcement, the executive directors are Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi, Ms. Wong Sau Kuen and Mr. Liu Kwok Wah, and the independent non-executive directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.

* *For identification purpose only*